The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two new rescue therapies for “off” periods are or soon will be available (i.e., Inbrija, APL-130277); and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Gocovri, Nuplazid) or are in late-phase development (e.g., P2B001, TD-9855). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales of PD therapies. However, given the cost-sensitivity of PD patients and the widespread availability of generic and—for many patients—therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.
What will be the impact of forthcoming levodopa reformulations?
Will they alter the PD treatment paradigm or be sidelined by access hurdles and/or physician resistance? What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in PD?
How do neurologists differentiate among levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which of these therapies will enjoy the greatest clinical and commercial success in this highly generic market?
United States, France, Germany, Italy, Spain, United Kingdom, Japan.Primary research: 32 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.
Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.
Emerging therapies: Phase II: 24 drugs; Phase III: 6 drugs; preregistration: 1 drug.
Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2028, segmented by brands/generics.
Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Eisai, Hisamitsu Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, Theravance Biopharma, UCB, US WorldMeds, Zambon Pharma.Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951, AP-CD/LD, APL-130277, Duodopa/Duopa, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, Trerief, Xadago.